Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

NCT00031733 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Intraocular Melanoma
Melanoma (Skin)

Interventions

BIOLOGICAL: MART-1 antigen
BIOLOGICAL: gp100 antigen
BIOLOGICAL: incomplete Freund's adjuvant
BIOLOGICAL: recombinant interleukin-12
BIOLOGICAL: sargramostim
BIOLOGICAL: tyrosinase peptide
DRUG: alum adjuvant
PROCEDURE: adjuvant therapy

Sponsor

University of Southern California

Collaborators

[object Object]